They focused on three vaccines routinely given in adolescence: Tdap, which guards against tetanus, diphtheria, and acellular pertussis; the meningococcal conjugate vaccine, or MCV4; and the vaccine that protects against HPV.
What does MCV stand for?
MCV stands for Meningococcal Conjugate Vaccine
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of MCV
We have 118 other meanings of MCV in our Acronym Attic
- Maladies Cardio Vasculaires (French: Cardiovascular Disease)
- maritime crew visa
- Maritiome Commission, Victory Ship (US Navy)
- Maximum Capacity Vehicle (Dacia Logan; UK)
- McConnell Valdes (legal partnership in Puerto Rico)
- Mean Cell Volume
- Mean Corpuscular Volume
- Measles-Containing Vaccine
- Medical College of Virginia
- Meningitis Conjugated Vaccine
- Merck Capital Ventures, LLC (investment)
- Mesoscale Convective Vortex
- Mid-Cap Value (finance)
- Middlesex County Volunteers Fifes and Drums (est. 1982; Massachusetts)
- Midland Cogeneration Venture (Midland, Michigan)
- Military College of Vermont
- Mission Critical Variant (test and evaluation)
- Mobile Car Valeting (UK and Ireland)
- Mobile Construction Vehicle
- Mobile Coordinating Vehicle (US FEMA)
Samples in periodicals archive:
Interventions are urgently needed to increase the uptake of meningococcal conjugate vaccine, particularly in light of the new recommendation for a booster dose, and the substantial proportion of parents .
ATLANTA -- The tetravalent meningococcal conjugate vaccine is now recommended for all 11- to 18-year-olds instead of select age groups, according to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
FROM A MEETING OF THE CDC'S ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES ATLANTA--A booster dose of meningococcal conjugate vaccine should be given to adolescents at 16 years of age if they received a first dose at age 11-12 years, and a booster should be given 5 years after the first dose--up to age 21 years--to those who first received the vaccine at age 13-15 years.
Although this vaccine generates a robust immune response against serogroup W-135, in contrast to what has been demonstrated for serogroup C meningococcal conjugate vaccines (37), meningococcal polysaccharide vaccines are not thought to reliably prevent asymptomatic carriage.